Compare HubSpot Inc (HUBS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Mesoblast Limited — how do they compare? HubSpot Inc trades at $211.21 (market cap $11.00B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: HubSpot Inc is far larger — about 5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | MESO | |
|---|---|---|
Market Cap | $11.00B | $2.21B |
Sector | Technology | Technology |
52-Week High | $522.97 | $20.96 |
52-Week Low | $170.39 | $12.88 |
Enterprise Value | $9.89B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $215.91, up 2.64% today but remains in a bearish technical trend. The company reported strong Q2 2026 earnings with EPS of $3.26 beating estimates, but lowered customer growth guidance to 5,000-6,000 per quarter. Revenue grew 20% year-over-year to $3.13 billion in 2025, with net income improving to $45.91 million. However, the stock faces headwinds from AI transition costs and a securities fraud investigation announced on August 10, 2026.
Despite near-term challenges, HubSpot maintains strong fundamentals with 76.6% analyst buy ratings and a $233.93 consensus target. The AI pivot creates execution risk but offers long-term growth potential. Key risks include customer acquisition slowdown, competitive pressures, and legal uncertainties. Current valuation at 78.5x P/E requires sustained execution for further upside.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
